Filing Details

Accession Number:
0001753926-25-000800
Form Type:
13G Filing
Publication Date:
2025-05-12 20:00:00
Filed By:
3i, LP
Company:
Cannabics Pharmaceuticals Inc. (OTCMKTS:CNBX)
Filing Date:
2025-05-13
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Beneficially Owned Number of Shares Beneficially Owned Number of Aggregate Shares Percent of Class
3i, LP 0 3,420,088 9.9%
3i Management LLC 0 3,420,088 9.9%
Maier Joshua Tarlow 0 3,420,088 9.9%
Filing





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G



Comment for Type of Reporting Person:  As more fully described in Item 4 of this Amendment No. 4 to Statement on Schedule 13G (''Amendment No. 4''), such shares and percentage are based on 33,861,352 shares of common stock, par value $0.0001 per share, of the issuer (the ''Common Stock'') outstanding as of February 28, 2025, as disclosed in the issuer's Quarterly Report on Form 10-Q for the fiscal period ended February 28, 2025, filed by the issuer with the U.S. Securities and Exchange Commission (the ''SEC'') on April 14, 2025 (the ''Form 10-Q''). Beneficial ownership consists of 3,046,323 shares of Common Stock held directly by the reporting person and 373,765 shares of Common Stock issuable upon conversion of a senior secured convertible note (the ''Note'') held directly by the reporting person, which conversion is subject to a 9.99% beneficial ownership limitation provision (the ''Blocker'').


SCHEDULE 13G



Comment for Type of Reporting Person:  As more fully described in Item 4 of this Amendment No. 4, such shares and percentage are based on 33,861,352 shares of Common Stock outstanding as of February 28, 2025, as disclosed in the Form 10-Q. Beneficial ownership consists of 3,046,323 shares of Common Stock held indirectly by the reporting person and 373,765 shares of Common Stock issuable upon conversion of the Note held indirectly by the reporting person, which conversion is subject to a 9.99% Blocker.


SCHEDULE 13G



Comment for Type of Reporting Person:  As more fully described in Item 4 of this Amendment No. 4, such shares and percentage are based on 33,861,352 shares of Common Stock outstanding as of February 28, 2025, as disclosed in the Form 10-Q. Beneficial ownership consists of 3,046,323 shares of Common Stock held indirectly by the reporting person and 373,765 shares of Common Stock issuable upon conversion of the Note held indirectly by the reporting person, which conversion is subject to a 9.99% Blocker.


SCHEDULE 13G


 
3i, LP
 
Signature:/s/ 3i, LP
Name/Title:Maier Joshua Tarlow, Manager of 3i Management LLC, General Partner of 3i, LP
Date:05/13/2025
 
3i Management LLC
 
Signature:/s/ 3i Management LLC
Name/Title:Maier Joshua Tarlow, Manager
Date:05/13/2025
 
Maier Joshua Tarlow
 
Signature:/s/ Maier Joshua Tarlow
Name/Title:Maier Joshua Tarlow
Date:05/13/2025

Comments accompanying signature:  LIST OF EXHIBITS Exhibit No. 1 - Joint Filing Agreement, dated March 6, 2023 (incorporated by reference to Exhibit 1 to the Schedule 13G filed by the Reporting Persons with the SEC on March 6, 2023).